INmune Bio (INMB) Set to Post Quarterly Earnings on Thursday

INmune Bio (NASDAQ:INMB) is expected to post its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to announce earnings of ($0.1467) per share and revenue of $1.88 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 3:30 PM ET.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.16.

INmune Bio Price Performance

Shares of NASDAQ INMB opened at $1.43 on Tuesday. The stock’s fifty day moving average price is $2.05 and its two-hundred day moving average price is $1.64. INmune Bio has a one year low of $1.09 and a one year high of $2.60. The firm has a market cap of $39.68 million, a price-to-earnings ratio of -2.13 and a beta of 0.89.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on INMB shares. Weiss Ratings raised INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 19th. Wall Street Zen upgraded shares of INmune Bio from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, INmune Bio currently has an average rating of “Moderate Buy”.

About INmune Bio

INmune Bio, Inc is a clinical-stage biotechnology company focused on developing treatments that harness and modulate the innate immune system. The company’s research is aimed at addressing diseases in which chronic inflammation or impaired immune function plays a significant role, including cancer, neurodegenerative disorders and certain psychiatric conditions.

Its lead product candidate is XPro, a next-generation tumor necrosis factor inhibitor designed to selectively neutralize soluble TNF while preserving transmembrane TNF signaling.